2018年系统性红斑狼疮研究新进展

doi:10.35541/cjd.20190298

Abstract

Luo Shuaihantian, Long Hai, Lu Qianjin. Advances in systemic lupus erythematosus in 2018[J]. Chinese Journal of Dermatology, 2020, 53(8): 665-667.doi:10.35541/cjd.20190298

References ［29］

［1］	Yen EY, Shaheen M, Woo J, et al. 46⁃year trends in systemic lupus erythematosus mortality in the United States, 1968 to 2013: a nationwide population⁃based study［J］. Ann Intern Med, 2017,167（11）:777⁃785. doi: 10.7326/M17⁃0102.
［2］	Yen EY, Singh RR. Brief report: lupus⁃an unrecognized leading cause of death in young females: a population⁃based study using nationwide death certificates, 2000 -2015［J］. Arthritis Rheumatol, 2018,70（8）:1251⁃1255. doi: 10.1002/art.40512.
［3］	Ward MM. Education level and mortality in systemic lupus erythematosus （SLE）: evidence of underascertainment of deaths due to SLE in ethnic minorities with low education levels［J］. Arthritis Rheum, 2004,51（4）:616⁃624. doi:10.1002/art.20526.
［4］	Zhao M, Sun Y, Gao F, et al. Epigenetics and SLE: RFX1 downregulation causes CD11a and CD70 overexpression by altering epigenetic modifications in lupus CD4+ T cells［J］. J Autoimmun, 2010,35（1）:58⁃69. doi:10.1016/j.jaut.2010.02.002.
［5］	Zhao M, Tan Y, Peng Q, et al. IL⁃6/STAT3 pathway induced deficiency of RFX1 contributes to Th17⁃dependent autoimmune diseases via epigenetic regulation［J］. Nat Commun, 2018,9（1）:583. doi: 10.1038/s41467⁃018⁃02890⁃0.
［6］	Gorji AE, Roudbari Z, Alizadeh A, et al. Investigation of systemic lupus erythematosus （SLE） with integrating transcriptomics and genome wide association information［J］. Gene, 2019,706:181⁃187. doi:10.1016/j.gene.2019.05.004.
［7］	Wang YF, Zhang Y, Zhu Z, et al. Identification of ST3AGL4, MFHAS1, CSNK2A2 and CD226 as loci associated with systemic lupus erythematosus （SLE） and evaluation of SLE genetics in drug repositioning［J］. Ann Rheum Dis, 2018,77（7）:1078⁃1084. doi: 10.1136/annrheumdis⁃2018⁃213093.
［8］	Lim J, Bae SC, Kim K. Understanding HLA associations from SNP summary association statistics［J］. Sci Rep, 2019,9（1）:1337. doi: 10.1038/s41598⁃018⁃37840⁃9.
［9］	Chen X, Sun X, Yang W, et al. An autoimmune disease variant of IgG1 modulates B cell activation and differentiation［J］. Science, 2018,362（6415）:700⁃705. doi: 10.1126/science.aap 9310.
［10］	Urowitz MB, Bookman AA, Koehler BE, et al. The bimodal mortality pattern of systemic lupus erythematosus［J］. Am J Med, 1976,60（2）:221⁃225.
［11］	Bengtsson C, Ohman ML, Nived O, et al. Cardiovascular event in systemic lupus erythematosus in northern Sweden: incidence and predictors in a 7⁃year follow⁃up study［J］. Lupus, 2012,21（4）:452⁃459. doi: 10.1177/0961203311425524.
［12］	Schoenfeld SR, Kasturi S, Costenbader KH. The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review［J］. Semin Arthritis Rheum, 2013,43（1）:77⁃95. doi:10.1016/j.semarthrit.2012.12.002.
［13］	Manzi S, Meilahn EN, Rairie JE, et al. Age⁃specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study［J］. Am J Epidemiol, 1997,145（5）:408⁃415. doi: 10.1093/oxfordjournals.aje.a009122.
［14］	Leonard D, Svenungsson E, Dahlqvist J, et al. Novel gene variants associated with cardiovascular disease in systemic lupus erythematosus and rheumatoid arthritis［J］. Ann Rheum Dis, 2018,77（7）:1063⁃1069. doi: 10.1136/annrheumdis⁃2017⁃212614.
［15］	Tsai F, Homan PJ, Agrawal H, et al. Bim suppresses the development of SLE by limiting myeloid inflammatory responses［J］. J Exp Med, 2017,214（12）:3753⁃3773. doi:10.1084/jem. 20170479.
［16］	Antignani A, Segal D, Simon N, et al. Essential role for Bim in mediating the apoptotic and antitumor activities of immunotoxins［J］. Oncogene, 2017,36（35）:4953⁃4962. doi: 10.1038/onc.2017. 111.
［17］	Shukla S, Saxena S, Singh BK, et al. BH3⁃only protein BIM: an emerging target in chemotherapy［J］. Eur J Cell Biol, 2017,96（8）:728⁃738. doi: 10.1016/j.ejcb.2017.09.002.
［18］	Larosa M, Zen M, Gatto M, et al. IL⁃12 and IL⁃23/Th17 axis in systemic lupus erythematosus［J］. Exp Biol Med （Maywood）, 2019,244（1）:42⁃51. doi: 10.1177/1535370218824547.
［19］	van Vollenhoven RF, Hahn BH, Tsokos GC, et al. Efficacy and safety of ustekinumab, an IL⁃12 and IL⁃23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double⁃blind, phase 2, randomised, controlled study［J］. Lancet, 2018,392（10155）:1330⁃1339. doi: 10.1016/S0140⁃6736（18）32167⁃6.
［20］	Hahn BH. Belimumab for systemic lupus erythematosus［J］. N Engl J Med, 2013,368（16）:1528⁃1535. doi: 10.1056/NEJMct120 7259.
［21］	Zhang F, Bae SC, Bass D, et al. A pivotal phase III, randomised, placebo⁃controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea［J］. Ann Rheum Dis, 2018,77（3）:355⁃363. doi: 10.1136/annrheumdis⁃2017⁃211631.
［22］	Markham A. Baricitinib: first global approval［J］. Drugs, 2017,77（6）:697⁃704. doi:10.1007/s40265⁃017⁃0723⁃3.
［23］	Taylor PC, Keystone EC, van der Heijde D, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis［J］. N Engl J Med, 2017,376（7）:652⁃662. doi: 10.1056/NEJMoa160 8345.
［24］	Richez C, Truchetet ME, Kostine M, et al. Efficacy of baricitinib in the treatment of rheumatoid arthritis［J］. Expert Opin Pharmacother, 2017,18（13）:1399⁃1407. doi:10.1080/14656566.2017.1359256.
［25］	Wallace DJ, Furie RA, Tanaka Y, et al. Baricitinib for systemic lupus erythematosus: a double⁃blind, randomised, placebo⁃controlled, phase 2 trial［J］. Lancet, 2018,392（10143）:222⁃231. doi:10.1016/S0140⁃6736（18）31363⁃1.
［26］	Werth VP, Merrill JT. A double⁃blind, randomized, placebo⁃controlled, phase II trial of baricitinib for systemic lupus erythematosus: how to optimize lupus trials to examine effects on cutaneous lupus erythematosus［J］. Br J Dermatol, 2019,180（5）:964⁃965. doi:10.1111/bjd.17344.
［27］	Dispenza MC, Regan JA, Bochner BS. Potential applications of Bruton′s tyrosine kinase inhibitors for the prevention of allergic reactions［J］. Expert Rev Clin Immunol, 2017,13（10）:921⁃923. doi: 10.1080/1744666X.2017.1370374.
［28］	Seiler T, Dreyling M. Bruton′s tyrosine kinase inhibitors in B⁃cell lymphoma: current experience and future perspectives［J］. Expert Opin Investig Drugs, 2017,26（8）:909⁃915. doi: 10.1080/13543784.2017.1349097.
［29］	Chalmers SA, Glynn E, Garcia SJ, et al. BTK inhibition ameliorates kidney disease in spontaneous lupus nephritis［J］. Clin Immunol, 2018,197:205⁃218. doi:10.1016/j.clim.2018.10. 008.

[1]	Zhou Tong, Geng Songmei. Application of biologic agents in the treatment of bullous pemphigoid [J]. Chinese Journal of Dermatology, 2023, 56(8): 789-793.
[2]	He Suling, Tian Xin, Liang Jingyao, Shao Lei, Li Junlong, Huang Qiongxiao, Liu Yumei, Wang Jianqin. Skin microecology in patients with severe atopic dermatitis at acute and remission phases [J]. Chinese Journal of Dermatology, 2022, 55(4): 329-336.
[3]	Zhou Chu, Wen Long, Wang Peiru, Wang Xiuli, . Application of photoacoustic imaging in the diagnosis and treatment of skin tumors [J]. Chinese Journal of Dermatology, 2021, 54(3): 256-259.
[4]	Zhu Beibei, Li Jing, Huang Huiyao, Li Ning, Liu Lijun, Zhang Lihua, Huan Jing, Ni Qi, Hou Wei, Liu Yi, Yang Xueyuan. Analysis of clinical trials of dermatological drugs in China, 2020 [J]. Chinese Journal of Dermatology, 2021, 54(11): 1001-1004.
[5]	Chen Lijun, Li Tingting, Zhao Juan, Zeng Ying, Wang Peng, Kang Xiaojing. Screening of DNA methylation sites associated with melanoma and construction of an aberrant methylation profile: a preliminary study [J]. Chinese Journal of Dermatology, 2021, 54(11): 966-972.
[6]	Zhong Caimei, He Sihua, Zhao Weifeng, Zhong Jianneng, Zhou Meifeng, Deng Yuhua. Effect of nasal parasitism by Demodex mites on nasal skin microbiome in patients with rosacea [J]. Chinese Journal of Dermatology, 2020, 53(5): 345-351.
[7]	He Suling, Tian Xin, Chen Lijie, Li Junlong, Wang Jianqin, Liu Yumei . Application of metagenomics in atopic dermatitis [J]. Chinese Journal of Dermatology, 2020, 53(4): 311-314.
[8]	Yang Xiaoxiao, Zheng Na′na, Zhong Liansheng, Pan Zhiqiang, Yu Zeyu. Changes in methylation status of the whole genome and GCH1 gene in patients with herpes zoster neuralgia [J]. Chinese Journal of Dermatology, 2019, 52(6): 420-424.
[9]	Zhong Caimei, Deng Yuhua, Zhou Meifeng, Zhao Weifeng. Effect of age and gender on bacteria and fungi on the healthy face of adults [J]. Chinese Journal of Dermatology, 2019, 52(12): 889-898.
[10]	Qi-Quan CHEN. [J]. Chinese Journal of Dermatology, 2015, 48(4): 274-274.
[11]	. Butyl flufenamate ointment in the treatment of solar dermatitis: a clinical observation [J]. Chinese Journal of Dermatology, 2014, 47(6): 431-432.
[12]	GUO Qing, ZENG Fan-qin, CHEN Jian-hao, CHEN Hui-xia, ZHU Shuang. The treatment efficacy of 308-nm excimer laser for vitiligo [J]. Chinese Journal of Dermatology, 2007, 40(4): 193-195.
[13]	HUANG Qiong, YANG Qin-ping, FANG Xu, HAN Ling, ZHENG Zhi-zhong, FU Wen-wen, SUN Jian-fang, JIANG Yi-qun, GU Jun, GAO Chun-fang, XU Ai-e, CHEN Jun-fan, SU Bing-hua, HE Qing-bo. Treatment of psoriasis vulgaris with a recombinant human tumor necrosis factor receptor:Fc fusion protein:a multicentre, randomized, double blind trial [J]. Chinese Journal of Dermatology, 2007, 40(11): 655-658.
[14]	GONG Juan-qin, LIN Lin, HAO Fei, CHEN Yan, ZENG Fan-qin, LI Bo-you, BI Zhi-gang, ZHANG Mei-hua, YI Dong, ZHAO Bian. Staphylococcus aureus Colonization in Eczema and Atopic Dermatitis and Therapeutic effect of Combined Topical Treatment [J]. Chinese Journal of Dermatology, 2004, 37(9): 515-518.
[15]	WANG Ai-ping, TU Ping, JI Su-zhen, WU Yan, SHEN Yue, ZHU Xue-Jun. Clinical Efficacy of Benzoyl Peroxide Gel with Different Concentrations in Acne Vulgaris [J]. Chinese Journal of Dermatology, 2003, 36(6): 313-315.

Advances in systemic lupus erythematosus in 2018

PDF

PDF (Mobile)

Knowledge

Abstract

Cite this article

share this article

References ［29］

Related Articles 15

Metrics

Comments

Recommended 10